ZUO Zhong, Joan 左中
Director and Professor
School of Pharmacy
Faculty of Medicine
The Chinese University of Hong Kong
Tel: (852) 3943 6862
Fax:(852) 2603 5295
Professor Joan Zuo is the Director and Professor of the School of Pharmacy at the Chinese University of Hong Kong. She holds a B. Sc. and a Ph.D. in Pharmaceutical Sciences and has had over 20 years’ experience in the biopharmaceutics and pharmacokinetics fields. Since she joined the School of Pharmacy at the Chinese University of Hong Kong in Jan 2000, Prof. Zuo has secured over 10 million continuous supports from various grant agencies such as University Grant Council, Innovation Technology Foundation, Food and Health Bureau, Hospital Authority in Hong Kong SAR as PI to support her series investigations on bioactive herbal components. The mechanistic findings on the absorption and metabolism of these components have been applied to areas such as in vitroand in vivo quality control of herbal products, improvement in delivery of herbal components in vivo, elucidation or even prediction of potential herb/herb or herb/drug interactions in vivo. Prof. Zuo’s research findings in the above fields have generated over 300 original research and conference papers and patents of USA, China, Hong Kong and Malaysia. Currently, Prof. Zuo is serving as editorial board member for Biopharmaceutics and Drug Dispositions, Xenobiotica and grant reviewer for China and Macau, and journal reviewer for more than 50 international peer reviewed journals. In 2011, Prof. Zuo was elected to be the member of Nomination Committee of the International Society of Xenobiotics (ISSX) aiming to promote excellent xenobiotics research/researchers in the Asia Pacific region.
- Biopharmaceutics and pharmacokinetics, pharmaceutical analysis, drug metabolisms in gut and drug delivery technology;
- Absorption, pharmacokinetics and formulation study of the active components in traditional Chinese medicine (TCM) and herbal medicine;
- Herb-drug interactions investigations using preclinical, clinical and systematic reviews approaches;
- Biopharmaceutics, pharmacokinetics, herb-drug interactions
Recent and On-going Research Grants
(* as PI)
- *Impact of the Chinese herbal medicines on the combination therapy with clopidogrel and aspirin: pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats. Sponsored by Food and Health Bureau – Health and Medical Research Fund during the period 2015-07-20 to 2017-07-19 for the sum of HKD 909,000
- *Evaluation of Potential Herb-drug Interactions between Oseltamivir and Commonly Used Anti-influenza Chinese Medicinal Herbs sponsored by Food and Health Bureau – Health and Medical Research Fund during the period 2014-03-03 to 2016-03-02 for the sum of HKD 982,010.00
- * CNS Uptake of Radix Scutellariae Flavones and Relationships with its Anxiolytic Effects (CU13798) sponsored by Research Grants Council – General Research Fund during the period 2014-01-01 to 2015-12-31 for the sum of HKD 562,921.00
- * Is It Safe to Take Danshen-Gegen Product with Warfarin and Aspirin? A Pilot Study in Human Subject (MD12756) sponsored by Food and Health Bureau – Health and Medical Research Fund during the period 2013-06-01 to 2015-12-31 for the sum of HKD 985,982.00
- Chinese Medicine to Overcome Resistant Chemotherapy: Comparison of the Effects of Tripterygium wilfordii with Other Selected Herbal Extracts in Cell Models of Resistant Lung, Pancreatic and Prostate Cancers (MD12893) sponsored by Macau University of Science and Technology Foundation during the period 2013-01-09 to 2015-08-31 for the sum of HKD 342,904.00
- Refining the bioactivity of P42, a hit therapeutic peptide, and developing a combined therapeutic peptide approach for treating Huntington’s Disease. (BL14398) sponsored by ANR/RGC Joint Research Scheme during the period 2015-04-01 to 2019-03-31 for the sum of HKD 2,540,083.00
- Orally-dissolving Films for Overcoming Biopharmaceutic Challenges of Drug Molecules (MD14612) sponsored by Innovation & Technology Commission-Innovation and Technology Support Programme during the period 2015-03-01 to 2016-02-29 for the sum of HKD 963,700.00
- Clinical Assessment of a Topical Application Containing Radix Rubiae for Plaque-Type Psoriasis – A Randomized, Double-blind, Vehicle-controlled and Left-Right Comparison Pilot Study (MD14926) sponsored by Food and Health Bureau – Health and Medical Research Fund during the period 2015-02-01 to 2016-07-31 for the sum of HKD 937,274.00
- Targeting RNA and Protein Toxicities of Polyglutamine Diseases Using Peptidylic Inhibitors (BL14370) sponsored by Vice-Chancellor’s One-off Discretionary Fund during the period 2015-01-01 to 2019-01-31 for the sum of HKD 2,500,000.00
- Oral Delivery of Poorly Soluble Traditional Chinese Medicine (MD13364) sponsored by CUHK Research Committee Funding (Direct Grants) during the period 2014-06-30 to 2015-06-29 for the sum of HKD 80,000.00
- Targeting RNA and Protein Toxicities of Polyglutamine Diseases Using Peptidylic Inhibitors (BL13801) sponsored by RGC – Collaborative Research Fund (CRF) during the period 2014-06-01 to 2017-05-31 for the sum of HKD 7,044,220.00
- Targeting RNA and Protein Toxicities of Polyglutamine Diseases Using Peptidylic Inhibitors (BL13976) sponsored by Research Committee Group Research Scheme during the period 2014-06-01 to 2017-05-31 for the sum of HKD 818,110.00
- Bachelor of Pharmacy Programme
- PHAR2520 Fundamentals of Herbal Medicines
- PHAR2213 Pharmaceutical Product Development & Manufacturing
- PHAR2220 Biopharmaceutics Pharmacokinetics
- PHAR3510 Complementary and Alternative Medicine
- Master of Science in Pharmaceutical Manufacturing and Quality
- PHAR5130 Overview of Drug Development
- PHAR5521 Formulation and Process Development
- PHAR5613 Bioavailability & Bioequivalence
- PHAR5579 Graduation Project II
(* Corresponding Author)
- Lyu CM, Zhang YF, Zhou WB, Zhang S, Kou F, Wei H, Zhang N, Zuo Z*. Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence. The AAPS Journal.2016; 18(2):432-444.
- Zhang Z, Ge BK, Zhou LM, Lam TN, Zuo Z*. Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. Journal of Ethnopharmacology 2015; 154(3): 672-686.
- Wong YC, Qian S, Zuo Z*. Pharmacokinetic Comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in Nasal Drug Delivery. Pharm Res. 2014; DOI 10.1007/s11095-014-1312-8.
- Fong SYK, Liu M, Wei H, Lobenberg R, Kanfer I, Lee VHL, Amidon GL, Zuo Z*. Establishing the pharmaceutical quality of Chinese herbal medicine: a provisional BCS classification. Molecular Pharmaceutics. 2013; 10(5):1623-1643.
- Xie C, Wang ZJ, Wang C, Xu J, Wen ZN, Wang HT, Shi LM, Chow MSS, Huang Y, Zuo Z*. Utilization of gene expression signature for quality control of traditional Chinese medicine formula Si-Wu-Tang. The AAPS Journal.2013; 15(3):884-892.
- Li CR, Zhang L, Zhou LM, Wo SK, Lin G, Zuo Z*. Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in radix scutellariae. AAPS Journal. 2012; 14 (1): 23-34.
- Wang L, Wang ZJ, Wo SK, Lau CBS, Chen XA, Huang M, Lee VHL, Chow MSS, Zuo Z*. A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to Si-Wu-Tang. International Journal of Pharmaceutics. 2011; 406(1-2): 99-105.
- Zhang L, Li CR, Lin G, Krajcsi P, Zuo Z*. Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters –In vitro and in vivo evidences. AAPS Journal. 2011; 13(3): 378-389.
- Zhang L, Lin G, Zuo Z*. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharmaceutical Research. 2007; 24(1): 81-89.
- Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, Zuo Z*. Mechanistic study on the intestinal absorption and disposition of baicalein. European Journal of Pharmaceutical Sciences. 2007; 31(3-4): 221-231.
- Teacher of the Year Award 2003/2004, School of Pharmacy, CUHK
- Chow MSS, Wang YF, Zuo Z. “Method of enhancing absorptions of transmucosal administration formulations”, USA Patent No. US 7,329,416 B2, granted on Feb. 12, 2008; Chinese Patent No. 200580030149.3, granted March 24, 2010; Hong Kong Patent No. HK1107271, granted on May 31, 2010; Malaysian Patent No. MY-141878-A, granted on July 16, 2010.
- Chow MSS, Wang YF, Zuo Z. “Method of enhancing absorptions of transmucosal administration formulations” continuation-in-part, USA Patent No. US 8,012,503 B2, granted on Sept. 6, 2011
- Chair of Pharmacy Internship Training Committee & Member, Pharmacy & Poison’s Board of Hong Kong, Department of Health, HKSAR Government
- Member, TCM Research and Development Committee, Innovation and Technology Bureau, HKSAR Government
- Member, Proprietary Traditional Chinese Medicine Registration Committee, Chinese Medicine Council of Hong Kong
- Member, Pharmacovigilance Advisory Body, Drug Office, Department of Health, HKSAR Government
- Editorial Board Member, Biopharmaceutics and Drug Dispositions, Xenobiotica, Chinese Medicine, and European Journal of Pharmaceutical Sciences (Regional Editor)
- Journal Reviewer for over 50 international peer-reviewed journal including Advanced Drug Delivery Review, Molecular Pharmaceutics, Pharmaceutical Research, Journal of Clinical Pharmacology, Journal of Pharmaceutical and Biomedical Analysis, etc.
- Grant Reviewer for NSFC, HMRF, Macau FDCT, Macau University, etc.